Vincent Linder,
Founder and President,
CDP BioMedical Consulting and CEO at Calciscon AG
BioMedical Consultant, Entrepreneur & Senior Biotech Executive with track record of success for biomedical devices. Partner with clients for value creation during all aspects of development of biomedical devices, from invention to commercialization.
Co-founder of Claros Diagnostics (a technology company spun out of Harvard University) with a successful $50M exit, completion of design & development activities, CE-mark and submission to FDA of a pre-market approval (PMA) as Chief Technology Officer of OPKO Diagnostics. The Claros® device is a point-of-care device that allows the quantitative determination of protein by immunoassay in a droplet of fingerstick blood. Technical and regulatory oversight for the launch of the 4Kscore®, a blood test for the early detection of prostate cancer.
Post-doctoral fellow at Harvard University (Prof. Whitesides), and Ph.D. in Switzerland from the Institute of Microtechnology, University of Neuchatel (Prof. de Rooij), in collaboration with the Insel University Hospital, and CSEM (Swiss Center of Electronics and Microtechnology).
Commercialization of Microfluidic Devices for Point-of-Care Applications
Thursday, 10 September 2020 at 11:30
Add to Calendar ▼2020-09-10 11:45:002020-09-10 12:45:00Europe/LondonThe T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) PatientsPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
This presentation will focus on the commercialization challenges specific to microfluidic devices for point-of-care applications. At an early stage of development, strategies can focus on de-risking analytical and clinical performances and may overlook other critical aspects of the design. For a successful commercialization effort, it is essential to implement at the onset of the program a comprehensive vision encompassing the patient presenting in a POC setting, the POC user and all the steps needed to obtain an actionable test result. This presentation will focus on development hurdles commonly experienced by microfluid-based IVD companies, and directions/solutions to overcome them.
The T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) Patients
Thursday, 10 September 2020 at 11:45
Add to Calendar ▼2020-09-10 11:45:002020-09-10 12:45:00Europe/LondonThe T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) PatientsPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Despite multiple drugs and diagnostics used today, most chronic kidney disease (CKD) patients still die of cardiovascular (CV) complications, and a prognosis for CKD patients is often as poor as that of some solid tumors. Calciscon offers the T50 blood test to identify patients with elevated risk of CV complications. Then, treating physicians use the T50 result to coordinate interventions, repeat the T50 to assess the efficacy of their intervention, and adjust treatment as needed until the T50 improves. In this contribution we discuss the foundational work that led to the invention of the T50, and its clinical validation across multiple cohorts of CKD patients.
Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020Point-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-10 11:45:002020-09-10 12:45:00Europe/LondonThe T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) PatientsPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
